Ortho Clinical Diagnostics Holdings plc (OCDX)
| Market Cap | 4.66B |
| Revenue (ttm) | 1.72B |
| Net Income (ttm) | -169.40M |
| Shares Out | 216.58M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving...
Ortho Clinical Diagnostics, a Carlyle-backed global provider of in vitro diagnostic products, filed on Monday with the SEC to raise up to $100 million in an initial public offering. However, t...
Ortho Clinical Diagnostics Holdings plc has filed to go public with an IPO on the NASDAQ.
About OCDX
Ortho Clinical Diagnostics is a pure-play in vitro diagnostics (“IVD”) business driven by our credo, “Because Every Test is A Life.” This guiding principle reflects the crucial role diagnostics play in global health and guides our priorities as an organization. As a leader in IVD, we impact approximately 800,000 patients every day. We are dedicated to improving outcomes for these patients and saving lives through providing innovative and reliable diagnostic testing solutions to the clinical laboratory and transfusion medicine communitie... [Read more...]
| Industry Medical Devices | IPO Date Jan 28, 2021 |
| CEO Chris Smith | Employees 4,500 |
| Stock Exchange NASDAQ | Ticker Symbol OCDX |
Financial Performance
In 2019, OCDX's revenue was $1.80 billion, an increase of 0.79% compared to the previous year's $1.79 billion. Losses were -$156.90 million, -36.94% less than in 2018.